Antiretroviral therapy use during pregnancy and the risk of small for gestational age birth in a medicaid population

Pediatric Infectious Disease Journal

Volumn 34, Issue 7, 2015, Pages e169-e175

  Phiri, Kelesitse ^a   Williams, Paige L ^a   Dugan, Kate B ^a   Fischer, Michael A ^b   Cooper, William O ^c   Seage, George R ^a   Hernandez Diaz, Sonia ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

antiretroviral; HIV; medicaid; pregnancy; small for gestational age

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; ALCOHOL CONSUMPTION; ANTIRETROVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG USE; FEMALE; FETUS DEATH; FIRST TRIMESTER PREGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL DISEASE; MATERNAL SMOKING; MEDICAID; MONOTHERAPY; NEWBORN; PREGNANCY; PREGNANT WOMAN; PREMATURE LABOR; PRENATAL CARE; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; SECOND TRIMESTER PREGNANCY; SMALL FOR DATE INFANT; COHORT ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; MIDDLE AGED; PREGNANCY COMPLICATIONS, INFECTIOUS; PREMATURE BIRTH; PROCEDURES; RISK ASSESSMENT; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INFANT, SMALL FOR GESTATIONAL AGE; MEDICAID; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREMATURE BIRTH; RISK ASSESSMENT; UNITED STATES; YOUNG ADULT;

EID: 84942783028     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000712     Document Type: Article

References (31)

1. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants; 2010. Available at: http://www.who.int/hiv/pub/mtct/antiretroviral2010/en/. Accessed April 28, 2015.
2. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf. Accessed January 10, 2014.
3. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS. 1998; 12: F241-F247.
4. European Collaborative Study, Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS. 2000; 14: 2913-2920.
5. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: The health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr. 2003; 32: 380-387.
6. Thorne C, Patel D, Newell ML., Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS. 2004; 18: 2337-2339.
7. Townsend CL, Cortina-Borja M, Peckham CS, et al. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS. 2007; 21: 1019-1026.
8. Machado ES, Hofer CB, Costa TT, et al. Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Sex Transm Infect. 2009; 85: 82-87.
9. Powis KM, Kitch D, Ogwu A, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis. 2011; 204: 506-514.
10. Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis. 2012; 206: 1695-1705.
11. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002; 346: 1863-1870.
12. Tuomala RE, Watts DH, Li D, et al; Women and Infants Transmission Study. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr. 2005; 38: 449-473.
13. Morris AB, Dobles AR, Cu-Uvin S, et al. Protease inhibitor use in 233 pregnancies. J Acquir Immune Defic Syndr. 2005; 40: 30-33.
14. Cotter AM, Garcia AG, Duthely ML, et al. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis. 2006; 193: 1195-1201.
15. Patel K, Shapiro DE, Brogly SB, et al; P1025 team of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group. Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy. J Infect Dis. 2010; 201: 1035-1044.
16. Phiri K, Hernandez-Diaz S, Dugan KB, et al. First trimester exposure to antiretroviral therapy and risk of birth defects. Pediatr Infect Dis J. 2014; 33: 741-746.
17. Piper JM, Ray WA, Griffin MR, et al. Methodological issues in evaluating expanded Medicaid coverage for pregnant women. Am J Epidemiol. 1990; 132: 561-571.
18. Cooper WO, Hernandez-Diaz S, Gideon P, et al. Positive predictive value of computerized records for major congenital malformations. Pharmacoepidemiol Drug Saf. 2008; 17: 455-460.
19. Oken E, Kleinman KP, Rich-Edwards J, Gillman MW., A nearly continuous measure of birth weight for gestational age using a United States national reference. BMC Pediatr. 2003; 3: 6.
20. Phiri K, Fischer MA, Mogun H, et al. Trends in antiretroviral drug use during pregnancy among HIV-infected women on Medicaid: 2000-2007. AIDS Patient Care STDS. 2014; 28: 56-65.
21. National Vital Statistics System. Birth Data. Available at: http://www.cdc.gov/nchs/births.htm. Accessed December 11, 2012.
22. Briand N, Mandelbrot L, Le Chenadec J, et al; ANRS French Perinatal Cohort. No relation between in-utero exposure to HAART and intrauterine growth retardation. AIDS. 2009; 23: 1235-1243.
23. Watts DH, Williams PL, Kacanek D, et al; Pediatric HIV/AIDS Cohort Study. Combination antiretroviral use and preterm birth. J Infect Dis. 2013; 207: 612-621.
24. Bardeguez AD, Lindsey JC, Shannon M, et al; PACTG 1025 Protocol Team. Adherence to antiretrovirals among US women during and after pregnancy. J Acquir Immune Defic Syndr. 2008; 48: 408-417.
25. Kapetanovic S, Christensen S, Karim R, et al. Correlates of perinatal depression in HIV-infected women. AIDS Patient Care STDS. 2009; 23: 101-108.
26. Kreitchmann R, Harris DR, Kakehasi F, et al; NISDI LILAC Study Team. Antiretroviral adherence during pregnancy and postpartum in Latin America. AIDS Patient Care STDS. 2012; 26: 486-495.
27. Nachega JB, Uthman OA, Anderson J, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-Analysis. AIDS. 2012; 26: 2039-2052.
28. Dreyfuss ML, Msamanga GI, Spiegelman D, et al. Determinants of low birth weight among HIV-infected pregnant women in Tanzania. Am J Clin Nutr. 2001; 74: 814-826.
29. Ramokolo V, Lombard C, Fadnes LT, et al. HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants. J Nutr. 2014; 144: 42-48.
30. VanderWeele T, Vansteelandt S., Conceptual issues concerning mediation, interventions and composition. Statist Interface. 2009; 2: 457-468.
31. Centers for Disease Control and Prevention. HIV/AIDS. HIV among women fact sheet. Available at: http://www.cdc.gov/hiv/risk/gender/women/facts/. Accessed July 11, 2014.